Thanks to the support of Healthware Group as global co-host and main sponsor, and to the conference chairman, Roberto Ascione, Frontiers Health is recognised as one of the leading global health innovation events and has become the epicentre of the digital health ecosystem.

The conference agenda, in its second year as a hybrid physical-virtual experience, will feature partnership opportunities to run custom breakout sessions, corporate events, keynote speakers, discussion panels, plenary sessions, challenges, breakout sessions and more.

Themes

This year’s conference will explore topics inspired by healthcare, including:

Digital Therapeutics
Patent protections, regulatory developments, reimbursement strategies, data protection, open-sourcing healthcare

Digital Transformation
R&D transformation, health insurance trends, consumerization of healthcare, mjedical on-demand models, the connected patient

Telehealth
Patient centricity, remote monitoring, beyond episodic care, mental telehealth, big data & AI

Funding & Scaling
SPAC strategies, digital health IPOs, investments

Tickets

Take advantage of the Early Bird discount to get your ticket – digital or in-person – to attend the most important global event dedicated to digital health innovation!

Buy your pass to keep up to date with the global conference

Once a user stores the digital version of the COVID Card to their device, they will be able to access it via a shortcut on their device home screen, even when they are offline or in areas that have weak internet service.
To use this feature, the device needs to run Android 5 or later and be Play Protect certified. Installing the Google Pay app is not a requirement to access COVID Cards.

More info here

Example COVID Cards from Healthvana, a company serving Los Angeles County

MSD has announced the first Europe-wide Patient Digital Health Awards (PDHA.eu), a competition intended to directly involve patients and patient advocacy associations so as to highlight their needs and diverse experiences as drivers of digital health thinking.

Modeled after the highly successful Italian edition now in its fourth year, PDHA.eu 2021 was developed in collaboration with Digital Health Academy to inspire and recognize digital healthcare innovation from a patient perspective. It applauds solutions aimed at improving care and quality of life for patients and their caregivers, particularly those developed collaboratively with patients and/or advocacy organizations.

The competition is open to individuals, patient associations, healthcare providers, scientific foundations, public or private universities and educational institutions, services companies, IT companies, and startups that are located within any of the EU Member States, EFTA Members, the Balkans, and the UK.

Applications must be submitted by 25 July 2021, 12:00 am CET.

The award categories are: Digital Prevention and Diagnostics, Mental Health, and Social Support, New Ways to Interact with Healthcare Teams and Providers, Disease Monitoring and Therapeutics, and Returning to Care (post-pandemic).

More than merely an award, the PDHA.eu initiative bolsters the vital role of healthcare innovation at the rapidly evolving intersection of technology and science, for both patients and providers.

PDHA.eu’s commitment to putting patients first, from the project themes to the judging panel members, truly sets it apart, as do its goals of sparking innovation, connecting patients and innovators, and creating a positive synergy within the communities.

For more information and to enter the competition, visit www.pdha.eu today!

The updated report includes a total of 24 companies from the Nordic countries showcasing their solutions and ambitions, especially chosen for their relevance to the japanese market.

The Nordics and Japan have much in common, and face many of the same challenges. Both regions are relatively affluent, and technologically advanced. Both face an aging population and dwindling workforce, necessitating innovative solutions in healthcare technologies. The Nordic healthcare ecosystems are globally renowned for providing efficient, high-quality, population-wide health-care systems.

Nordic Healthtech has never been more relevant, especially in the wake of the COVID-19 pandemic. There is an urgent need for introducing solutions that enable remote monitoring and treatment of patients, and provide tools for prevention, earlier diagnosis, and self-help.

Download the full report

The World Health Organization (WHO) and the Federal Republic of Germany will establish a new global hub for pandemic and epidemic intelligence, data, surveillance and analytics innovation. The Hub, based in Berlin and working with partners around the world, will lead innovations in data analytics across the largest network of global data to predict, prevent, detect prepare for and respond to pandemic and epidemic risks worldwide.

H.E. German Federal Chancellor Dr Angela Merkel said:

The current Covid-19 pandemic has taught us that we can only fight pandemics and epidemics together. The new WHO Hub will be a global platform for pandemic prevention, bringing together various governmental, academic and private sector institutions. I am delighted that WHO chose Berlin as its location and invite partners from all around the world to contribute to the WHO hub.

The WHO Hub for Pandemic and Epidemic Intelligence is part of WHO’s Health Emergencies Programme and will be a new collaboration of countries and partners worldwide, driving innovations to increase availability and linkage of diverse data; develop tools and predictive models for risk analysis; and to monitor disease control measures, community acceptance and infodemics. Critically, the WHO Hub will support the work of public health experts and policy-makers in all countries with insights so they can take rapid decisions to prevent and respond to future public health emergencies.

We need to identify pandemic and epidemic risks as quickly as possible, wherever they occur in the world. For that aim, we need to strengthen the global early warning surveillance system with improved collection of health-related data and inter-disciplinary risk analysis, said Jens Spahn, German Minister of Health. “Germany has consistently been committed to support WHO’s work in preparing for and responding to health emergencies, and the WHO Hub is a concrete initiative that will make the world safer.

Working with partners globally, the WHO Hub will drive a scale-up in innovation for existing forecasting and early warning capacities in WHO and Member States. At the same time, the WHO Hub will accelerate global collaborations across public and private sector organizations, academia, and international partner networks. It will help them to collaborate and co-create the necessary tools for managing and analyzing data for early warning surveillance. It will also promote greater access to data and information.

One of the lessons of COVID-19 is that world needs a significant leap forward in data analysis to help leaders make informed public health decisions, said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. This requires harnessing the potential of advanced technologies such as artificial intelligence, combining diverse data sources, and collaborating across multiple disciplines. Better data and better analytics will lead to better decisions.

The Series D funding round was led by CPP Investments (CPPIB) and Fidelity Management & Research LLC with participation from existing investors, including the Ontario Teachers’ Pension Plan (Ontario Teachers’), Index Ventures, Accel, Creandum and Project A.

Kry will use the investment to scale its platform, building on both its operations as a healthcare provider and its innovative software offerings as well as further geographic expansion. This will bring the benefits of its technology to millions more patients across Europe.

Kry, the European leader in digital healthcare whose technology connects patients with qualified healthcare professionals, will widen clinician access to its product suite. More healthcare professionals will have greater access to use Kry’s digital tools to deliver high-quality healthcare to patients across Europe. Beyond Kry’s core video consultation technology, which is already available in 30 European markets, clinicians will be able to access enhanced triage, advanced queuing and matching functionality, paperless referral management, secure patient messaging and personalised treatment plans.

Kry will continue to deepen the functionalities of its patient-facing app and expand its mental health offering to more markets including adding Internet Cognitive Behavioural Therapy (ICBT) and mental health self-assessment tools. Patients will be able to access a wider range of healthcare professionals such as psychologists, dermatologists, physiotherapists, and pediatricians. Furthermore, it will invest in digital healthcare tools to support chronic healthcare conditions.

Johannes Schildt, CEO and co-founder of Kry, said:

This investment will help us empower patients to make active choices about their health in partnership with thousands of public and private healthcare professionals in Europe.
Working in partnership with healthcare systems, governments, and clinicians, we can deliver high quality healthcare, improve patient access, and create healthier societies.
We have played a leading role in the digitization of healthcare across Europe and will continue to play a leading role in the creation of a global digital healthcare ecosystem to deliver better patient experiences and outcomes through our technology.

Leon Pedersen, Managing Director and Head of Thematic Investing, CPP Investments said:

Kry is a significant and successful player in Europe’s digital healthcare market and this investment is a strong fit with our innovations in healthcare strategy. We are pleased to support Kry as they leverage technology to advance the delivery of proactive patient-centric services.

Kry, which has been growing rapidly since it was founded in 2015, has helped over three million patients access healthcare to date. The company grew over 100% year-on-year in 2020 in response to supporting patients and healthcare systems across Europe during the pandemic. The new funding will help the company meet the increasing patient demand for their virtual healthcare services and fulfil its vision of making high-quality healthcare accessible for all.

Kry will also use the additional funding to grow its team and explore further acquisitions and strategic partnerships.

J.P. Morgan acted as Lead Placement Agent and Goldman Sachs acted as Placement Agent on the Series D round.

For further information please contact press@kry.health

This year, Frontiers has been a global Hybrid conference. In line with the “new normal” situation, the format of the 2020 edition has been hybrid, combining online global streaming together with offline events and activities held at hubs in multiple locations such as Italy, Germany, Finland, Spain, the USA, Switzerland and more.

It has been dedicated to digital health innovation in the context of the “new normal”, focusing on telemedicine, digital therapies, breakthrough technologies, patient-centricity, healthcare transformation and ecosystem development.

You can read the full live coverage on the pharmaphorum dedicated pages: Day 1 – Day 2

Yes, you read it right.

Frontiers Health is changing format, combining online and offline events and different activities in Italy, Germany, Finland, Spain, USA and many other locations.

Join us on the 12^th and 13^th of November

The Frontiers Health Global conference will go live in a new hybrid and engaging format, which has already proven effective with the Frontiers Health Live event held in May.
In fact, 7 hours of live coverage reached over 20,000 users worldwide.

The local hubs will host the iconic breakouts and plenary sessions. So attendees from all over the world will enjoy the pure Frontiers Health conference spirit, on line and also offline.

In fact, they could take advantage of the “silent conference” experience, designed for off line attendees.

Don’t miss the Start-up Discovery and the networking opportunities in dedicated virtual rooms.

Get your ticket now

MRC Epidemiology Unit launches study to monitor COVID-19 in 12,000 Cambridgeshire residents – MRC Epidemiology Unit

SAFE2GO Contact Tracing App to Help UK Businesses Open Safely – digit.fyi

Emotional empathy is driving brand equity – pharmaphorum

Smell and taste loss could help identify COVID-19 at airports, say researchers – pharmaphorum

HealthTunes launches iOS APP to deliver stress and anxiety relief to healthcare workers and beyond – Healthware Group

The clinical trial collaboration focuses on utilizing remote diagnostic monitoring through the use of precision medicine clinical-grade, cloth-based wearable technology. The goal is to monitor patients with confirmed or suspected COVID-19 with Nanowear’s proprietary and patented cloth-based nanosensors which detect physiological and biomarker changes indicative of clinical deterioration that may require further intervention from the hospital systems.

Nanowear’s digital platform enables a radical leap forward in telemedicine and remote patient diagnostics. When a patient wears SimpleSENSE, Nanowear’s one-size-fits-all adjustable undergarment, physicians can remotely capture and assess multiple physiological signals – including real-time ECG, systolic and diastolic blood pressure, blood flow hemodynamics, respiration, lung volume and fluid, and temperature trends – without the need for an in-person visit or physical touch.

When we talk about telemedicine, we often talk about video conferencing, said Venk Varadan, Co-founder and CEO. But to truly enable remote diagnostics we must incorporate clinical-grade remote monitoring that is affordable, comfortable, and simple for patients to use. Nanowear’s SimpleSENSE replaces a stethoscope, blood pressure cuff, multi-channel Holter monitor, and Capnogram (End-tidal CO2), providing a diagnostic quality monitoring system in a form factor that is easy to ship, easy to wear, and easy for the patient to use. Nanowear’s garment captures 120 million data points per patient per day across cardiac, pulmonary, and circulatory biomarker data, which is transmitted to clinical staff, so that they may make informed and quicker decisions remotely.

The COVID-19 pandemic has transformed healthcare delivery and diagnosis; the traditional experience of a physician physically examining or touching a patient in-person has been altered, perhaps forever, and could have a lasting impact on the future of patient-physician physical interactions expansively from primary care to chronic disease cases.

As New York City, the epicenter of the global coronavirus pandemic, emerges from coronavirus lockdown, health systems are looking for novel technologies like Nanowear to better understand and combat the unprecedented severity of COVID-19. Nanowear is being used to aid in COVID-19 diagnosis to ensure the health and safety of patients and medical professionals.

What we need to understand about COVID-19 is why certain patients develop a cytokine mediated immune response from the virus, said national Principal Investigator of the collaboration, Sameer Jamal, MD, of Hackensack Meridian Health, the largest health system in New Jersey. This resulting inflammation within the circulatory system often leads to severe complications or death, which we have seen first-hand in New York City and the surrounding area. Diagnosis and co-morbidities alone is not enough to determine risk to admitted patients before they need to be transferred to ICU. Nanowear’s SimpleSENSE is giving us an exponential amount of relevant data metrics about the heart and lungs from an all-in-one product that should ultimately enable us to triage lower risk patients and stratify high risk patients.

While the immediate need for hospitals across the US is to remotely diagnose and assess worsening COVID-19 instances from home-to-hospital and hospital-to-home, the virus itself has changed the paradigm for healthcare delivery in general.

The COVID-19 paradigm shift has accelerated healthcare systems’ need to implement staff-contactless monitoring involving acute and chronic disease-related hospitalizations, said John Marshall, MD, Head of Emergency Department at Maimonides Medical Center in Brooklyn, New York. “The continuity of in-patient monitoring, patient-to-home monitoring, and at-home monitoring across 8-10 biomarkers with a very easy-to-use product is what makes Nanowear’s solution compelling and unique.

Unlike consumer-grade wearable garments, smartwatches, smartrings or limited-metric adhesive patches, Nanowear’s textile-embedded multi-parameter nanosensors are clinical-grade, analyzing multiple cardiac, pulmonary, and circulatory biomarkers, creating a holistic personalized digital signature for each patient. The garment transmits these diagnostic health signals to a mobile application and physician portal, enabling healthcare professionals to assess a wide range of medical conditions, from diabetes, high blood pressure and congestive heart failure (CHF), to acute illness, discomfort, and stress.

Nanowear’s core of cloth-nanotechnology sensors is a differentiator from smartwatches, adhesive patches, and other medical or consumer wearables, said Suraj Kapa, MD, of Mayo Clinic. With billions of touchpoints per centimeter and large vectors across the heart and lungs, Nanowear’s skin-to-impedance barrier is lower than other wearable sensors, resulting in location-agnostic, high signal-to-noise raw data from basic skin contact. The breadth of metrics, quality and quantity of data, and comfortable user experience are key for machine learning algorithms in various diagnostic verticals, even beyond healthcare.

Nanowear’s proprietary and patented cloth-based nanotechnology was invented by Co-founder and Chief Innovation Officer, Dr. Vijay Varadan and founding engineers, Dr. Pratyush Rai, Prashanth Shyam Kumar, Mouli Ramasamy and Dr. Gyanesh Mathur. SimpleSENSE achieved first-on-man status in late 2019 in the NanoSENSE Heart Failure validation study led by national Principal Investigator John Boehmer, MD, Director of Penn State Hershey Medical Center’s Heart and Vascular Institute. Hackensack Meridian Health Systems and Medical University of South Carolina are also participating in the NanoSENSE Heart Failure study.

Nanowear has submitted its SimpleSENSE device and mobile platform to FDA for Class II 510(k) clearance. SimpleSENSE is not yet FDA-cleared and currently not intended to mitigate, prevent, treat, cure or diagnose any disease or condition.